Testing of the Akt/PKB Inhibitor MK-2206 by the Pediatric Preclinical Testing Program

BACKGROUND: MK-2206 is a small molecule allosteric inhibitor of Akt/PKB that is undergoing clinical trials for treatment of cancer. PROCEDURES: MK-2206 was tested against the PPTP in vitro panel using a 96 hour exposure (1.0 nM-10 μM), and in vivo using thrice weekly dosing for a planned 4 weeks at...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Gorlick, Richard, Maris, John M., Houghton, Peter J., Lock, Richard, Carol, Hernan, Kurmasheva, Raushan T., Kolb, E. Anders, Keir, Stephen T., Reynolds, C. Patrick, Kang, Min H., Billups, Catherine A., Smith, Malcolm A.
Формат: Artigo
Язык:Inglês
Опубликовано: 2011
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3290691/
https://ncbi.nlm.nih.gov/pubmed/22102563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.23412
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы